Diaxonhit announced consolidated earnings results for the full year ended December 31, 2013. The company reported consolidated income as of December 31, 2013 at EUR 30.5 million, an increase of 8% compared to pro forma income of EUR 28.2 million as of December 31, 2012. Total sales of in vitro diagnostic products recorded within Diaxonhit's commercial activities, reached EUR 26.3 million, an increase of 11% compared to sales of EUR 23.8 million recorded for the year 2012.